Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IMLT19000, Turner, RPL-16-001, Solid Tumor, RP1, Nivolumab

Research Question:
Is the drug RP1 alone and in combination with nivolumab safe and well tolerated in adult subjects with advanced and/or refractory solid tumors?

Basic Study Information

Purpose:
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

Location: University of Rochester Medical Center
Study Reference #: IMLT19000

Lead Researcher (Principal Investigator)

Lead Researcher:  Rachael Turner

Study Contact Information

Study Coordinator: Nichole Ransom
Phone: +1 585-276-8747
Email: nichole_ransom@urmc.rochester.edu

Additional Study Details

Return to Search